APA (7th ed.) Citation

LM, B., JA, D., VS, M., M, M., B, S., RJ, B., . . . AL, P. (2024). The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancreatic ductal adenocarcinoma. British journal of cancer, 131(10), 1694. https://doi.org/10.1038/s41416-024-02869-3

Chicago Style (17th ed.) Citation

LM, Badder, Davies JA, Meniel VS, Marušková M, Salvador-Barbero B, Bayliss RJ, Phesse TJ, Hogan C, and Parker AL. "The αvβ6 Integrin Specific Virotherapy, Ad5NULL-A20.FCU1, Selectively Delivers Potent "In-tumour" Chemotherapy to Pancreatic Ductal Adenocarcinoma." British Journal of Cancer 131, no. 10 (2024): 1694. https://doi.org/10.1038/s41416-024-02869-3.

MLA (9th ed.) Citation

LM, Badder, et al. "The αvβ6 Integrin Specific Virotherapy, Ad5NULL-A20.FCU1, Selectively Delivers Potent "In-tumour" Chemotherapy to Pancreatic Ductal Adenocarcinoma." British Journal of Cancer, vol. 131, no. 10, 2024, p. 1694, https://doi.org/10.1038/s41416-024-02869-3.